Sanofi-aventis announced today the official change in the legal denomination of the Aventis Pasteur company, which will henceforth be named sanofi pasteur. The General Meeting of Shareholders of Aventis Pasteur, held in December 2004, voted the change in name from Aventis Pasteur to sanofi pasteur. The Aventis Pasteur MSD joint venture, equally owned by Aventis Pasteur and Merck & Co. Inc.
Jean-François DEHECQ, Chairman and CEO of Sanofi-aventis, is currently accompanying Philippe DOUSTE-BLAZY, French Minister for Humanitarian aid, Health and the Family in his mission to Colombo, Sri-Lanka, to provide six tons of Sanofi-aventis medicines, consisting of 70,000 packs of antibiotics, anti-diarrhea medicines and antibacterial treatments. Within the framework of a humanitarian initia
Sanofi-aventis announced today its plan to reimburse the short-term tranche of the syndicated credit line which was put in place in April 2004 to finance the acquisition of Aventis (Tranche A). This 5 billion-Euro tranche is maturing on January 24, 2005. The company had an option to extend maturity for a maximum of one year. However, in order to optimise its financing costs, sanofi-aventis has
Sequential Taxotere following epirubicin-based regimen demonstrates survival advantage Aventis, part of the sanofi-aventis Group announced today that the results of a large phase III study demonstrated that sequential TAXOTERE (docetaxel) Injection Concentrate-based regimen significantly improved overall survival of women with operable, node-positive early stage breast cancer compared to a s
Since April 26, 2004, when Sanofi-Synthélabo and Aventis agreed to create sanofi-aventis, it has been confirmed that the headquarters of the new sanofi-aventis Group is to be located in Paris. Sanofi-aventis announced today that the Aventis site located in Schiltigheim will cease its activity during the course of next year. The business activity will be transfered to Paris. The French Wor
Aventis, part of the sanofi-aventis Group, announced today that it had sent to Genta a notice of termination of the agreements entered into by the two companies in 2002 and concerning the development of Genasense® (oblimersen sodium). At the time the agreements with Genta were entered into, Aventis was seeking a late-stage development opportunity that could potentially provide for a near term
~ First Major Advance in the Postsurgical Treatment Of Early-Stage Colon Cancer in More Than a Decade ~ Sanofi-Synthelabo, a member of the sanofi-aventis Group announced today that the US Food and Drug Administration (FDA) has approved ELOXATIN, in combination with conventional chemotherapy (infusional 5-fluorouracil/leucovorin, known as 5-FU/LV), for the adjuvant (postsurgical) treatment of
Aventis, part of the sanofi-aventis Group announced today that the European Commission has approved Taxotere®(docetaxel) Injection Concentrate for use in combination with prednisone as a treatment for men with androgen independent (hormone-refractory) metastatic prostate cancer. The Commission approval is based on the results of a large landmark phase III clinical trial, TAX 327, which demonst
Behovet av BPH-relaterad kirurgi reduceras Resultaten av ALFAUR-studien (ALFuzosin in Acute Urinary Retention), som presenterades vid European Association of Urologys (EAU) kongress i Wien, visar att den uroselektiva alfa1-blockeraren alfuzosin 10 mg en gång dagligen (OD = once daily) kan ha en positiv effekt på behandlingen av män som lider av akut urinretention (AUR). Akut urinretention (u
En ny studie ska ge svar på hur en vanlig form av hjärtsvikt kan behandlas. Ungefär hälften av alla patienter med hjärtsvikt har en normal sk. systolisk funktion.
Sanofi-Synthelabo AB har förstärkt verksamheten genom att tillsätta Tommy Olin som operativ chef.